October 7, 2026
Matchpoint Therapeutics
Matchpoint Therapeutics is advancing its covalent T-cell modulator MPT-062 toward clinical proof of concept.
- Round
- Series B
- Amount raised
- $150M
- Lead investor
- Nextech Invest
- Industry
- Biotechnology, Precision Medicine
- Headquarters
- United States
- Employees
- 11-50 employees
- Website
- —
- View profile →
Other investors
- Norwest Venture Partners
- Sanofi Ventures